Rapamycin and Aging: Insights from the PEARL Trial on Safety and Healthspan Enhancements After One Year
The PEARL trial demonstrates that low-dose, intermittent rapamycin is safe in healthy aging adults and improves lean tissue mass and pain in women, with additional benefits in emotional well-being and general health at lower doses.